Genprex Inc at LD Micro Main Event Transcript
Good afternoon and welcome to Genprex. I'd like to introduce the CFO, Ryan Confer.
All right. Thank you all for being here. Again, my name is Ryan Confer. I'm the Chief Financial Officer of Genprex. We are pioneering gene therapies for extremely large patient populations.
So just a quick note on our forward-looking statements. Anybody interested in investing in Genprex, highly encourage you to check out our website, particular our IR website, where you can read any of our SEC filings including all of our risk factors and our most recent 10-K.
So here at Genprex, we believe we have several key competitive advantages. First, we are targeting extremely large markets where patient populations have critical unmet needs with their current therapies. With cancer, and our oncology program in particular, we have a really unique non-viral gene therapy platform, which makes it very unlike every other treatment option out there. It is the first systemic gene therapy used for cancer in humans.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |